Table 2.
Baseline CTC counts detected using the GILUPI CellCollector, EPISPOT assay and CellSearch® system and clinical characteristics of 85 patients with localized PCa at baseline, according to the development of metastases during the follow-up period.
| Variable | Metastatic | Non-Metastatic | p |
|---|---|---|---|
| CTC (GILUPI), median (range) | 1 (0–3) | 1 (0–7) | 0.493 |
| CTC (GILUPI), n (%) | 15/25 (60%) | 35/60 (58%) | 0.542 |
| CTC (EPISPOT), median (range) | 1 (0–25) | 1 (0–4) | 0.421 |
| CTC (EPISPOT), n (%) | 13/24 (54%) | 32/58 (55%) | 0.562 |
| CTC (CellSearch®), median (range) | 0 (0–3) | 0 (0–54) | 0.822 |
| CTC (CellSearch®), n (%) | 3/20 (15%) | 7/50 (14%) | 0.591 |
| CTC (any assay), n (%) | 21/25 (84%) | 51/60 (85%) | 0.572 |
| PSA (ng/mL), median (range) | 28.2 (2.5–191.0) | 28.5 (0.5–136.9) | 0.971 |
| PSA ≥ 20 ng/mL, n (%) | 17/25 (68%) | 49/60 (82%) | 0.138 |
| Gleason Sum, median (range) | 7 (6–9) | 7 (6–9) | 0.164 |
| Gleason Sum ≥ 8, n (%) | 7/25 (28%) | 12/60 (20%) | 0.296 |
| cT ≥ 2c, n (%) | 16/24 (67%) | 19/60 (32%) | 0.004 |